This post was authored by Tanisha M. Sullivan, Senior Corporate Counsel, Sanofi US, who was recently elected President, National Association for the Advancement of Colored People (NAACP) – Boston Branch. Here, in honor of Black History Month, she shares her story about what led to her election to the associationâ€™s oldest chapter, with just under […]VIEW FULL POST
This post was authored by Lisa Egbuonu-Davis, M.D., Vice President, Global Patient Centered Outcomes & Solutions, who, in honor of Black History Month, shares her story about why she is committed to supporting gifted students from underrepresented minorities and socioeconomic disadvantaged groups. Lisa is a graduate of the Johns Hopkins School of Medicine and Bloomberg […]VIEW FULL POST
For full financial data and non-GAAP reconciliations, please refer to Sanofiâ€™s 2016 Annual Results and Presentation issued February 8, 2017, available at http://en.sanofi.com/investors/investors.aspx.
More information is also available via the press release.
Author: Kristin Schuhwerk, VP, Global Head of Clinical Operations, Sanofi
This past November, my colleague Paul Deutsch shared some valuable information about Phase 1 clinical trials, as part of our Drug Development 101 series. Today, Iâ€™d like to build on this information by providing some insight on what comes after Phase 1 clinical trials â€“ Phase […]